JP2010508030A5 - - Google Patents

Download PDF

Info

Publication number
JP2010508030A5
JP2010508030A5 JP2009534896A JP2009534896A JP2010508030A5 JP 2010508030 A5 JP2010508030 A5 JP 2010508030A5 JP 2009534896 A JP2009534896 A JP 2009534896A JP 2009534896 A JP2009534896 A JP 2009534896A JP 2010508030 A5 JP2010508030 A5 JP 2010508030A5
Authority
JP
Japan
Prior art keywords
protein
vaccine
nucleic acid
amino acid
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009534896A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010508030A (ja
JP5442442B2 (ja
Filing date
Publication date
Priority claimed from US11/923,326 external-priority patent/US8202967B2/en
Application filed filed Critical
Publication of JP2010508030A publication Critical patent/JP2010508030A/ja
Publication of JP2010508030A5 publication Critical patent/JP2010508030A5/ja
Application granted granted Critical
Publication of JP5442442B2 publication Critical patent/JP5442442B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009534896A 2006-10-27 2007-10-26 新規h5タンパク質、それらをコードする核酸分子およびベクター、ならびにそれらの医薬的使用 Active JP5442442B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86314206P 2006-10-27 2006-10-27
US60/863,142 2006-10-27
US11/923,326 US8202967B2 (en) 2006-10-27 2007-10-24 H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
US11/923,326 2007-10-24
PCT/US2007/082699 WO2008052173A2 (en) 2006-10-27 2007-10-26 Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013165132A Division JP2014012008A (ja) 2006-10-27 2013-08-08 新規h5タンパク質、それらをコードする核酸分子およびベクター、ならびにそれらの医薬的使用

Publications (3)

Publication Number Publication Date
JP2010508030A JP2010508030A (ja) 2010-03-18
JP2010508030A5 true JP2010508030A5 (enExample) 2010-12-16
JP5442442B2 JP5442442B2 (ja) 2014-03-12

Family

ID=39325469

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009534896A Active JP5442442B2 (ja) 2006-10-27 2007-10-26 新規h5タンパク質、それらをコードする核酸分子およびベクター、ならびにそれらの医薬的使用
JP2013165132A Withdrawn JP2014012008A (ja) 2006-10-27 2013-08-08 新規h5タンパク質、それらをコードする核酸分子およびベクター、ならびにそれらの医薬的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013165132A Withdrawn JP2014012008A (ja) 2006-10-27 2013-08-08 新規h5タンパク質、それらをコードする核酸分子およびベクター、ならびにそれらの医薬的使用

Country Status (18)

Country Link
US (3) US8202967B2 (enExample)
EP (1) EP2086576B8 (enExample)
JP (2) JP5442442B2 (enExample)
KR (2) KR101520307B1 (enExample)
AU (1) AU2007308869B2 (enExample)
BR (1) BRPI0718183B8 (enExample)
CA (1) CA2664914C (enExample)
CO (1) CO6210831A2 (enExample)
DK (1) DK2086576T3 (enExample)
ES (1) ES2391123T3 (enExample)
MX (1) MX2009004243A (enExample)
MY (1) MY150226A (enExample)
PL (1) PL2086576T3 (enExample)
PT (1) PT2086576E (enExample)
RU (1) RU2479589C2 (enExample)
SG (1) SG176419A1 (enExample)
SI (1) SI2086576T1 (enExample)
WO (1) WO2008052173A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056733A1 (es) * 2005-10-28 2007-10-17 Boehringer Ingelheim Vetmed Uso de vacunas para el tratamiento / prevencion de la transmision de patogenos
US8202967B2 (en) * 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
HUE028605T2 (en) 2007-03-14 2016-12-28 Takeda Vaccines Inc Cleaning virus-like particles
CN102271704A (zh) 2008-11-28 2011-12-07 梅里亚有限公司 重组禽流感疫苗及其用途
NZ602217A (en) * 2010-03-11 2014-08-29 Immune Design Corp Vaccines for influenza
WO2012047941A2 (en) 2010-10-04 2012-04-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
WO2014127825A1 (en) * 2013-02-21 2014-08-28 Boehringer Ingelheim Vetmedica Gmbh H5 proteins of h5n1 influenza virus for use as a medicament
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Umnファーマ ウイルス様粒子を含む培養物の製造方法
JOP20190088A1 (ar) 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
US12098166B2 (en) 2018-11-06 2024-09-24 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition against avian influenza virus H5 subtype
CN117229370B (zh) * 2022-06-08 2024-11-01 中科南京生命健康高等研究院 H5n6禽流感广谱性疫苗的开发及其应用
WO2026013162A1 (en) 2024-07-10 2026-01-15 Boehringer Ingelheim Vetmedica Gmbh Herpes virus of turkey vector based h5ha vaccine for the treatment and prevention of avian influenza infections in turkeys
WO2026013161A1 (en) 2024-07-10 2026-01-15 Boehringer Ingelheim Vetmedica Gmbh Prime and boost vaccination for the treatment and prevention of avian influenza infections in avians

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US382425A (en) 1888-05-08 Brandt
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4552758A (en) * 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Human use of avian-human reassortants as vaccines for influenza A virus
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP0386185A1 (fr) 1988-07-29 1990-09-12 IntraCel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
EP0737750B1 (en) 1989-03-21 2003-05-14 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5690938A (en) 1989-07-07 1997-11-25 Oravax, Inc. Oral immunization with multiple particulate antigen delivery system
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
US5643577A (en) 1990-04-24 1997-07-01 The University Of Newcastle Research Associates Limited Oral vaccine comprising antigen surface-associated with red blood cells
WO1992015672A1 (en) 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
DE69229390T2 (de) 1991-08-26 1999-11-11 Immuno Ag, Wien Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5807722A (en) 1992-10-30 1998-09-15 Bioengineering Resources, Inc. Biological production of acetic acid from waste gases with Clostridium ljungdahlii
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
EP0620277A1 (en) 1993-03-18 1994-10-19 Merck & Co. Inc. Nucleic acid pharmaceuticals
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
CA2181832C (en) 1994-01-27 2012-11-27 Harriet L. Robinson Immunization by inoculation of dna transcription unit
AU694519B2 (en) 1994-04-29 1998-07-23 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
CA2215162A1 (en) 1995-03-23 1996-09-26 Cantab Pharmaceuticals Research Limited Vectors for gene delivery
JP2002512501A (ja) 1996-07-03 2002-04-23 メリアル インコーポレイテッド 外来性dnaを含む組換えイヌアデノウィルス(cav)
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
PL205955B1 (pl) 2000-04-28 2010-06-30 St Jude Childrens Res Hospital Układ oparty na minimalnej liczbie plazmidów do wytwarzania infekcyjnych wirusów RNA o ujemnej nici, komórka gospodarza zawierająca taki układ, sposób wytwarzania wiriona wirusa RNA o ujemnej nici, sposób wytwarzania atenuowanego wirusa RNA o ujemnej nici, sposób wytwarzania zakaźnego wirusa o ujemnej nici do stosowania w szczepionkach i zastosowanie układu opartego na minimalnej liczbie plazmidów
WO2002003872A2 (en) 2000-07-11 2002-01-17 Johns Hopkins University Application of photochemotherapy for the treatment of cardiac arrhythmias
US20040071733A1 (en) * 2001-02-05 2004-04-15 Hiroshi Takaku Baculovirus vector vaccine
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
BR0314088A (pt) 2002-08-27 2005-07-19 Dow Agrosciences Llc Uso de toxina de escherichia coli lábil ao calor como um adjuvante em pássaros e aves domésticas
WO2005018539A2 (en) * 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US7601278B2 (en) 2003-07-04 2009-10-13 Nxp B.V. Precursor solution, method of preparation thereof and use thereof
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
EP2902484A1 (en) 2004-05-25 2015-08-05 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
CN1748795A (zh) * 2004-09-17 2006-03-22 金宁一 多价禽流感重组活载体疫苗
RU2283139C1 (ru) * 2005-03-21 2006-09-10 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения антигенов для вакцины против вирусов гриппа
KR20080052509A (ko) * 2005-04-11 2008-06-11 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션 유행성 독감 바이러스에 대한 백신
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
RU2483751C2 (ru) 2005-10-18 2013-06-10 Новавакс, Инк. ФУНКЦИОНАЛЬНЫЕ ВИРУСОПОДОБНЫЕ ЧАСТИЦЫ ГРИППА (VLPs)
AR056733A1 (es) 2005-10-28 2007-10-17 Boehringer Ingelheim Vetmed Uso de vacunas para el tratamiento / prevencion de la transmision de patogenos
WO2008033105A1 (en) 2006-09-13 2008-03-20 Dso National Laboratories Hemagglutinin antibody and uses thereof
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
EP2563389B1 (en) 2010-04-30 2015-07-08 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2014127825A1 (en) 2013-02-21 2014-08-28 Boehringer Ingelheim Vetmedica Gmbh H5 proteins of h5n1 influenza virus for use as a medicament

Similar Documents

Publication Publication Date Title
RU2609645C2 (ru) Экспрессионные системы
RU2009119597A (ru) Новые белки н5, кодирующие их молекулы нуклеиновых кислот и векторы, и их применение в медицине
JP2014527526A5 (enExample)
CA2821995C (en) Monomeric and multimeric peptides immunogenic against hiv
CN104780937A (zh) 涉及由多核苷酸编码的免疫原性多肽的新型初免-加强方案
JP2011528222A5 (enExample)
AR088028A1 (es) Proteinas h5, de h5n1 para un uso medicinal
CA2380833A1 (en) Proteins derived from white spot syndrome virus and uses thereof
CN104619718A (zh) 源自病毒蛋白的肽用作免疫原和配药成分
CN101186637A (zh) 抑制流感病毒感染的方法及其药物
JP7403733B2 (ja) インフルエンザhaスプリットワクチンの製造方法
JP2023522154A5 (enExample)
JP2020509770A5 (enExample)
CN101879312B (zh) 广谱型流感疫苗及其制备方法
JP2018533908A5 (enExample)
AU2016313660B2 (en) Polypeptide carrier for presenting target polypeptide and uses thereof
Li et al. A recombinant protein containing highly conserved hemagglutinin residues 81-122 of influenza H5N1 induces strong humoral and mucosal immune responses
ES2349153T3 (es) Inhibidores del virus de la hepatitis c.
EP2307036A1 (en) Novel peptide adjuvant for influenza vaccination
JP2019534242A5 (enExample)
CN113069540B (zh) 一种基于流感病毒载体的新型冠状病毒疫苗及其制备方法
TW202317600A (zh) 預防多種病毒感染的多價疫苗
CN103316357B (zh) 携带rsv基因的重组流感病毒嵌合疫苗及其制备方法
CN108348596A (zh) 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒
JPWO2002062381A1 (ja) バキュロウイルスベクターワクチン